zd-7155 has been researched along with Nerve-Degeneration* in 1 studies
1 other study(ies) available for zd-7155 and Nerve-Degeneration
Article | Year |
---|---|
Angiotensin type-1-receptor antagonists reduce 6-hydroxydopamine toxicity for dopaminergic neurons.
Angiotensin II activates (via type 1 receptors) NAD(P)H-dependent oxidases, which are a major source of superoxide, and is relevant in the pathogenesis of several cardiovascular diseases and certain degenerative changes associated with ageing. Given that there is a brain renin-angiotensin system and that oxidative stress is a key contributor to Parkinson's disease, we investigated the effects of angiotensin II and angiotensin type 1 (AT(1)) receptor antagonists in the 6-hydroxydopamine model of Parkinson's disease. Rats subjected to intraventricular injection of 6-hydroxydopamine showed bilateral reduction in the number of dopaminergic neurons and terminals. Injection of angiotensin alone did not induce any significant effect. However, angiotensin increased the toxic effect of 6-hydroxydopamine. Rats treated with the AT(1) receptor antagonist ZD 7155 and then 6-hydroxydopamine (with or without exogenous administration of angiotensin) showed a significant reduction in 6-hydroxydopamine-induced oxidative stress (lipid peroxidation and protein oxidation) and dopaminergic degeneration. Dopaminergic degeneration was also reduced by the NAD(P)H inhibitor apocynin. Angiotensin may play a pivotal role, via AT(1) receptors, in increasing the oxidative damage of dopaminergic cells, and treatment with AT(1) antagonists may reduce the progression of Parkinson's disease. Topics: Adrenergic Agents; Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Animals; Corpus Striatum; Dopamine; Drug Administration Schedule; Drug Interactions; Immunohistochemistry; Male; Mesencephalon; Naphthyridines; Nerve Degeneration; Neurons; Oxidopamine; Protein Carbonylation; Rats; Rats, Sprague-Dawley; Thiobarbituric Acid Reactive Substances; Tyrosine 3-Monooxygenase | 2007 |